SetPoint Medical

SetPoint Medical is a Valencia, California-based neurotechnology company pioneering the field of bioelectronic medicine through the development of an implantable device that targets the vagus nerve to treat chronic inflammatory diseases. The company's core technology delivers precisely calibrated electrical stimulation to the vagus nerve, activating the body's natural inflammatory reflex to suppress immune overactivity without the systemic side effects associated with traditional drug-based therapies. Their lead indication areas include rheumatoid arthritis and Crohn's disease, conditions that affect millions of patients worldwide and represent significant unmet medical need. By harnessing the nervous system as a therapeutic pathway, SetPoint Medical is working to offer patients a durable, non-pharmacological alternative to biologics and immunosuppressants.

SetPoint Medical has demonstrated meaningful clinical progress, with studies showing statistically significant reductions in disease activity in rheumatoid arthritis patients who had previously failed multiple biologic therapies. The company has advanced through pivotal clinical trials and has been building an evidence base that supports both the safety and efficacy of its platform technology. To date, SetPoint Medical has raised over 200 million dollars in funding through a Series E round, reflecting strong investor confidence in both the science and the commercial opportunity. These milestones position the company as one of the most clinically advanced bioelectronic medicine companies in the world.

SetPoint Medical represents a defining example of how neuromodulation is expanding beyond its traditional roots in pain and movement disorders into the broader terrain of systemic disease. Their work validates a new therapeutic category that could fundamentally change how inflammatory and autoimmune conditions are managed, reducing patient dependence on costly and side-effect-laden biologic drugs. For the neurotech industry, SetPoint Medical demonstrates that the nervous system can serve as a programmable interface for treating diseases once considered exclusively within the domain of pharmacology. As the bioelectronic medicine field continues to mature, SetPoint Medical stands as a critical proof-of-concept company whose clinical and commercial success could catalyze an entirely new generation of implantable, disease-modifying neurotechnologies.